SEC Tracker
Get the app

CRISPR Therapeutics CRSP

CRISPR Therapeutics reports executive stock options

James R. Kasinger, insider filing for CRSP

Form
4
Filed
Importance
Routine
  1. James R. Kasinger received 18,000 stock options on Oct 26, 2026
  2. 9,000 restricted stock units (shares paid out over time) granted on Oct 26, 2026
  3. Stock options vest over 48 months starting Nov 26, 2026

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when CRISPR Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
  2. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Merus MRUS
  5. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025